Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study explored using a chitosan oligomer coating for topical delivery of dutasteride-loaded nanostructured lipid carriers, aiming to reduce systemic exposure and cytotoxicity.

This study found that a lipid-based nanoparticle formulation with oleic acid for delivering dutasteride showed lower skin permeation compared to a formulation without oleic acid, indicating its potential for targeted dermal delivery.

This study demonstrated that testosterone treatment increases muscle strength and alters body composition in transmen, and the addition of dutasteride does not impair these anabolic effects.

This study found that co-administration of ketoconazole significantly altered the pharmacokinetics of dutasteride in rats, suggesting an interaction potential between dutasteride and azole antifungal drugs.

This study found that dutasteride use is associated with increased reports of sexual dysfunction, based on data from the U.S. Food and Drug Administration Adverse Event Reporting System.

This study reported that a liquid-liquid extraction method using methyl tert-butyl ether and methylene chloride was most effective for extracting dutasteride and its internal standard from rat plasma.

This study found that patients treated with dutasteride were significantly less likely to experience acute urinary retention and prostate-related surgeries compared to those treated with finasteride.

This review evaluates the use of 5α-reductase inhibitors in feminising hormone therapy, finding their additive feminising benefits unclear due to their specific action on testosterone conversion, with concerns highlighted regarding limited supporting evidence and safety signals, particularly for psychiatric and sexual effects.

This study reported that dutasteride, identified through a drug repurposing strategy, showed the potential to reduce neuroinflammation and cognitive impairment in LPS-stimulated models.

This study evaluated oral dutasteride for male androgenetic alopecia in a real-world setting, reporting that it effectively improved hair conditions in 90% of patients using monotherapy, with a good safety profile, particularly at low doses.

The source does not provide an abstract for this letter to the editor, so specific results regarding the long-term efficacy and safety of dutasteride for male androgenetic alopecia are not reported.

This study optimized the reaction conditions for the stereoselective hydrogenation of a compound used in manufacturing finasteride and dutasteride, improving the selectivity for the desired isomer.

This study found that oral dutasteride increased hair count more than intralesional administration in androgenetic alopecia, but more research is needed for a reliable comparison.

In this prospective phase II clinical trial, researchers are investigating whether adding dutasteride to combined androgen blockade can improve the response rate and clinical outcomes for patients with androgen receptor-positive recurrent or metastatic salivary duct carcinoma.

Dutasteride can stabilize hair loss in patients with frontal fibrosing alopecia, but its safety in women is unclear, so use it with caution.

This study reported that more sensitive, early diagnosis and treatment of COVID-19 with drug combinations significantly improved clinical outcomes in males with or without androgenetic alopecia, preventing severe progression.

This study found that a dutasteride tablet formulation using cyclodextrin complex, solubilizing polymer, and surfactant achieved similar bioavailability in beagle dogs to that of a commercial capsule.

This study found that dutasteride is not associated with an increased risk of osteoporosis or fractures in older men compared to finasteride, suggesting dutasteride does not adversely affect bone health.

This study found that dutasteride may reduce the likelihood of hospitalization for BPH-related surgery and newly detected prostate cancer, compared to finasteride, and suggests a budgetary benefit.

This study found that a dutasteride-loaded liposomal system significantly increased skin permeability and drug deposition in mouse skin compared to other formulations, suggesting improved localized treatment potential for androgenetic alopecia.

This study concluded that dutasteride modestly reduces nocturia in men but does not improve sleep quality.

In this study, the authors identified the DHRS9 SNP rs72623193 as most significantly associated with response to dutasteride in treating male pattern hair loss, with additional variants potentially contributing.

This study found that five 0.1 mg dutasteride capsules are bioequivalent to one 0.5 mg dutasteride capsule in healthy adult males under fasting conditions, and both were well tolerated.

This letter to the editor addresses corrections related to an earlier study on the effect of the dual 5α-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer, but reports no new findings.

This cohort study using real-world data found no significant difference in the risk of developing prostate cancer between finasteride and dutasteride among patients with benign prostatic hyperplasia, despite previous suggestions that dutasteride might be more effective.

In this study, dutasteride 1 mg daily reduced heavy drinking days and drinks per week among treatment-seeking men, particularly benefiting those with high baseline drinking to cope motives.

Taking dutasteride every other day works as well as daily and better preserves sexual function.

This letter to the editor presents no new research results; it discusses a combination of dutasteride intralesional microinjections with oral minoxidil versus oral minoxidil alone for treating androgenetic alopecia in men.

In this observational study, dutasteride treatment was associated with statistically significant stabilization of frontal fibrosing alopecia compared to other systemic therapies, with a dose-dependent effect observed across the frontal and bilateral temporal hairlines.

This case report suggests that dutasteride may be a potential cause of cerebral venous thrombosis, as observed in a 25-year-old male presenting with headache and diplopia that improved after discontinuing the drug.